ViiV Healthcare Premieres Early Data Showing Antiviral Activity Against Integrase Resistance from its Investigational, Third-Generation Integrase Inhibitor VH184

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced positive in vitro findings showing that an investigational integrase strand transfer inhibitor (INSTI), VH4524184 (VH184), retained its antiviral activity and could be effective in countering second-generation INSTI resistance.